Cargando…

Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 study

BACKGROUND: Selpercatinib, a highly selective and potent REarranged during Transfection (RET) kinase inhibitor, is effective in advanced RET-altered thyroid cancer (TC). However, the efficacy and safety in Chinese patients are unknown. PATIENTS AND METHODS: In the open-label, multi-center phase II L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Xiangqian, Ji, Qinghai, Sun, Yuping, Ge, Minghua, Zhang, Bin, Cheng, Ying, Lei, Shangtong, Shi, Feng, Guo, Ye, Li, Linfa, Chen, Lu, Shao, Jingxin, Zhang, Wanli, Gao, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434679/ https://www.ncbi.nlm.nih.gov/pubmed/36062046 http://dx.doi.org/10.1177/17588359221119318

Ejemplares similares

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial
por: Lu, Shun, et al.
Publicado: (2023)

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial
por: Cheng, Ying, et al.
Publicado: (2023)

Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
por: Lu, Shun, et al.
Publicado: (2022)

Selpercatinib monotherapy in a Chinese patient with RET fusion/EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report
por: Wu, Lin, et al.
Publicado: (2023)

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
por: Wirth, Lori J, et al.
Publicado: (2022)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021)

External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
por: Rolfo, C., et al.
Publicado: (2022)

Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial
por: Stinchcombe, Thomas E.
Publicado: (2023)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
por: Drilon, Alexander, et al.
Publicado: (2023)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects
por: Tsang, Venessa, et al.
Publicado: (2022)

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
por: Ortiz, Michael V., et al.
Publicado: (2020)

Clinical Activity of Selpercatinib in RET Mutant Pheochromocytoma-Case Reports
por: Konda, Bhavana, et al.
Publicado: (2021)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

Lenvatinib and selpercatinib successfully treated RET fusion gene-positive papillary thyroid carcinoma cardiac metastases: a case report
por: Toda, Soji, et al.
Publicado: (2023)

D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
por: Porcelli, Tommaso, et al.
Publicado: (2023)

Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea
por: Baek, Han-Sang, et al.
Publicado: (2023)

Neoadjuvant selpercatinib for advanced medullary thyroid cancer
por: Jozaghi, Yelda, et al.
Publicado: (2020)

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
por: Shen, Tao, et al.
Publicado: (2021)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
por: d'Arienzo, Paolo D., et al.
Publicado: (2023)

Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
por: Arora, Aakriti, et al.
Publicado: (2023)

Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer
por: Huang, Yan, et al.
Publicado: (2023)

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report
por: Leite, Caio Abner, et al.
Publicado: (2023)

Correction to: Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer
por: Ragnarsson, Oskar, et al.
Publicado: (2022)

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
por: Illini, Oliver, et al.
Publicado: (2021)

Ectopic Cushing’s Syndrome and Severe Hypocalcemia Due to Medullary Thyroid Cancer Responsive to Selpercatinib
por: Turin, Christie Gloria, et al.
Publicado: (2021)

Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma
por: Sitbon, Marine, et al.
Publicado: (2022)

An 83‐year‐old patient with RET fusion‐positive non‐small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration
por: Nakashima, Kazuhisa, et al.
Publicado: (2023)

Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib
por: Park, Ha-Young, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3oe55qd7dff1onf4b7rturgfa0